Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients

Archives of Surgery
P P ThomasO Jonasson

Abstract

Hepatitis is a frequent complication of dialysis and renal transplantation; therefore, the occurrence of drug hepatotoxicity is an additional important consideration in renal allograft recipients. Azathioprine, needed for immunosuppression, and isoniazid, used for antituberculous chemoprophylaxis, are both potentially hepatotoxic. A retrospective study of 119 patients who received 126 renal allografts was done to estimate the probable incidence of isoniazid-related hepatic dysfunction. All patients in this series were administered isoniazid chemoprophylaxis. Posttransplantation hepatitis developed in 13 patients. Circumstantial evidence supported a presumptive diagnosis of isoniazid hepatotoxicity in three recipients. We concluded that routine isoniazid chemoprophylaxis is not justified in renal allograft recipients based on the probability of hepatotoxicity as contrasted to the infrequent occurrence of tuberculosis.

Citations

May 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K V Rao, W R Anderson
Oct 27, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A K SubramanianUNKNOWN AST Infectious Diseases Community of Practice
Jan 28, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A SubramanianUNKNOWN AST Infectious Diseases Community of Practice
May 1, 1987·The Journal of Infection·G M SmithA M Geddes
Sep 1, 1987·Revista Do Instituto De Medicina Tropical De São Paulo·F J de PaulaE Sabbaga
Jul 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W C Maddrey, D H Van Thiel
Oct 11, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Robert H Rubin
Mar 1, 2019·Clinical Transplantation·Aruna K SubramanianUNKNOWN Infectious Diseases Community of Practice of the American Society of Transplantation
Jan 1, 1984·Acta Medica Scandinavica·T ForslundJ Edgren
Mar 16, 2021·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Jisu YuDong Kyu Oh
Jan 1, 1997·Clinical Microbiology Reviews·R Patel, C V Paya
Feb 29, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J WaiserH H Neumayer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.